LB Pharmaceuticals Inc (LBRX)
| Market Cap | 1.30B +243.7% |
| Revenue (ttm) | n/a |
| Net Income | -141.20M |
| EPS | -4.82 |
| Shares Out | 32.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,109 |
| Open | 40.31 |
| Previous Close | 40.30 |
| Day's Range | 38.67 - 41.71 |
| 52-Week Range | 15.19 - 50.16 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 58.00 (+44.78%) |
| Earnings Date | Nov 5, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 44.78% from the latest price.
News
LB Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
Schizophrenia Phase III data are expected in H1 2027, with bipolar depression data in 2028 and adjunctive MDD data in 2029; cash extends beyond Q2 2029. Priorities include efficacy, tolerability, and potential differentiation in EPS, cognition, and anhedonia.
LB Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
LB-102 combines NOVA 1 efficacy with low EPS and simple once-daily dosing; NOVA 2 schizophrenia data are expected in H1 2027. Funded milestones extend through MDD data in H1 2029, alongside mood-disorder expansion.
LB Pharmaceuticals expects cash equivalents to fund operations beyond Q2 2029
Cash, cash equivalents, and short-term investments of $403.8M as of September 30, 2026 expected to fund operations beyond Q2 2029, through multiple clinical milestones
LB Pharmaceuticals reports Q3 EPS ($1.79), consensus ($1.60)
“We recently strengthened our leadership team with the appointments of Dr. Susan Kozauer as Chief Medical Officer and Joe Miller as Chief Financial Officer, adding two highly accomplished executives w...
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Strengthened leadership with the appointment of Susan G. Kozauer, M.D.
LB Pharmaceuticals Earnings release: Q3 2026
LB Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
LB Pharmaceuticals Quarterly report: Q3 2026
LB Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
LB Pharmaceuticals Slides: Corporate presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
LB Pharmaceuticals Transcript: R&D Day 2026
NOVA-1 showed efficacy across doses, early improvement and signals in negative symptoms and cognition, alongside low EPS and minimal QTc prolongation. NOVA-2 data are expected H1 2027; bipolar depression and adjunctive MDD readouts are planned for 2028 and 2029.
LB Pharmaceuticals Slides: FY 2026
LB Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 27, 2026.
LB Pharmaceuticals management to meet with Piper Sandler
Meeting to be held in New York on October 29 hosted by Piper Sandler.
LB Pharmaceuticals to Participate in Upcoming Investor Events
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals Slides: Corporate presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
LB presents preclinical data ‘supporting’ LB-102’s mechanism of action
LB Pharmaceuticals (LBRX) announced the presentation of four posters at the 39th European College of Neuropsychopharmacology Congress, taking place in Munich, Germany from October 10-13, 2026. The pos...
LB Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $65 price target LB is developing novel therapeutics for central nervous system disorders, the a...
LB Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $65 price target
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
Guggenheim stats LB Pharmaceuticals at Buy, calls best idea
Guggenheim analyst Delma Caiati initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $80 price target The analyst named LB a best idea. LB-102 is a Phase 3…
LB Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $80 price target
LB Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded LB Pharmaceuticals (LBRX) to Neutral from Buy with a price target of $35, down from $37. Faster development and competitive setbacks “strengthen LB-102’s development value, but...
LB Pharmaceuticals initiated with a Buy at Needham
Needham initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $68 price target The company’s LB-102 is an improved version of amisulpride, one of the most effective antipsychotics…
LB Pharmaceuticals files automatic mixed securities shelf
16:09 EDT LB Pharmaceuticals (LBRX) files automatic mixed securities shelf
LB Pharmaceuticals Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
LB-102, a potent amisulpride derivative, shows robust efficacy and a favorable safety profile in schizophrenia, with potential expansion into mood disorders and Alzheimer's-related indications. Phase III data for schizophrenia is expected in the first half of next year.
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im...
LB Pharmaceuticals to Participate in Upcoming September Investor Events
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-im...